Neutrophil-Derived Myeloperoxidase and Hypochlorous Acid Critically Contribute to 20-Hydroxyeicosatetraenoic Acid Increases that Drive Postischemic Angiogenesis

Compensatory angiogenesis is an important adaptation for recovery from critical ischemia. We recently identified 20-hydroxyeicosatetraenoic acid (20-HETE) as a novel contributor of ischemia-induced angiogenesis. However, the precise mechanisms by which ischemia promotes 20-HETE increases that drive angiogenesis are unknown. This study aims to address the hypothesis that inflammatory neutrophil-derived myeloperoxidase (MPO) and hypochlorous acid (HOCl) critically contribute to 20-HETE increases leading to ischemic angiogenesis. Using Liquid Chromatography-Mass Spectrometry/Mass Spectrometry, Laser Doppler Perfusion Imaging, and Microvascular Density analysis, we found that neutrophil depletion and MPO knockout mitigate angiogenesis and 20-HETE production in the gracilis muscles of mice subjected to hindlimb ischemia. Furthermore, we found MPO and HOCl to be elevated in these tissues postischemia as assessed by immunofluorescence microscopy and in vivo live imaging of HOCl. Next, we demonstrated that the additions of either HOCl or an enzymatic system for generating HOCl to endothelial cells increase the expression of CYP4A11 and its product, 20-HETE. Finally, pharmacological interference of hypoxia inducible factor (HIF) signaling results in ablation of HOCl-induced CYP4A11 transcript and significant reductions in CYP4A11 protein. Collectively, we conclude that neutrophil-derived MPO and its product HOCl activate HIF-1α and CYP4A11 leading to increased 20-HETE production that drives postischemic compensatory angiogenesis. SIGNIFICANCE STATEMENT Traditionally, neutrophil derived MPO and HOCl are exclusively associated in the innate immunity as potent bactericidal/virucidal factors. The present study establishes a novel paradigm by proposing a unique function for MPO/HOCl as signaling agents that drive critical physiological angiogenesis by activating the CYP4A11-20-HETE signaling axis via a HIF-1α-dependent mechanism. The findings from this study potentially identify novel therapeutic targets for the treatment of ischemia and other diseases associated with abnormal angiogenesis.

[1]  W. Nauseef,et al.  Mammalian Heme Peroxidases , 2021 .

[2]  M. Davies.  Myeloperoxidase: Mechanisms, reactions and inhibition as a therapeutic strategy in inflammatory diseases. , 2020, Pharmacology & therapeutics.

[3]  K. Nelander,et al.  Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction , 2020, Clinical and translational science.

[4]  The Roles , 2020, Web and Digital for Graphic Designers.

[5]  A. Poveshchenko,et al.  Cytokine Profile in Experimental Models of Critical Limb Ischemia in Rats , 2019, Bulletin of Experimental Biology and Medicine.

[6]  J. Falck,et al.  CYP4A/20-HETE regulates ischemia-induced neovascularization via its actions on endothelial progenitor and preexisting endothelial cells. , 2019, American journal of physiology. Heart and circulatory physiology.

[7]  R. Stocker,et al.  Inhibition of MPO (Myeloperoxidase) Attenuates Endothelial Dysfunction in Mouse Models of Vascular Inflammation and Atherosclerosis. , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Schwartzman,et al.  20‐HETE in the regulation of vascular and cardiac function , 2018, Pharmacology & therapeutics.

[9]  P. Sleph,et al.  Potent Triazolopyridine Myeloperoxidase Inhibitors. , 2018, ACS medicinal chemistry letters.

[10]  A. Bongers,et al.  Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque , 2018, European heart journal.

[11]  O. Casanovas,et al.  Unraveling the Role of Angiogenesis in Cancer Ecosystems , 2018, Frontiers in Oncology.

[12]  L. Vanhamme,et al.  The other myeloperoxidase: Emerging functions. , 2018, Archives of biochemistry and biophysics.

[13]  Xin-Yu Zhang,et al.  Potential roles of myeloperoxidase and hypochlorous acid in metabolism and toxicity of alkene hydrocarbons and drug molecules containing olefinic moieties , 2017, Expert opinion on drug metabolism & toxicology.

[14]  I. Yoshino,et al.  Antifibrotic effects of cyclosporine A on TGF‐β1–treated lung fibroblasts and lungs from bleomycin‐treated mice: role of hypoxia‐inducible factor‐1α , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  J. Falck,et al.  Elevated 20-HETE impairs coronary collateral growth in metabolic syndrome via endothelial dysfunction. , 2017, American journal of physiology. Heart and circulatory physiology.

[16]  R. Stocker,et al.  The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture , 2016, Redox report : communications in free radical research.

[17]  T. Laskay,et al.  Changes in Neutrophil Metabolism upon Activation and Aging , 2018, Inflammation.

[18]  J. Falck,et al.  20-HETE contributes to ischemia-induced angiogenesis. , 2016, Vascular pharmacology.

[19]  A. Kettle,et al.  Reactive Oxygen Species and Neutrophil Function. , 2016, Annual review of biochemistry.

[20]  M. Mollenhauer,et al.  Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice. , 2016, International journal of cardiology.

[21]  P. Lermusiaux,et al.  Lower-extremity arterial revascularization: Is there any evidence for diabetic foot ulcer-healing? , 2016, Diabetes & metabolism.

[22]  A. Evdokiou,et al.  Uncovering a new role for peroxidase enzymes as drivers of angiogenesis. , 2015, The international journal of biochemistry & cell biology.

[23]  Samantha L. Hoopes,et al.  Vascular actions of 20-HETE. , 2015, Prostaglandins & other lipid mediators.

[24]  Nutan Srivastava,et al.  Granule Protein Processing and Regulated Secretion in Neutrophils , 2014, Front. Immunol..

[25]  J. Falck,et al.  20-HETE Regulates the Angiogenic Functions of Human Endothelial Progenitor Cells and Contributes to Angiogenesis In Vivo , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[26]  T. Mayadas,et al.  The multifaceted functions of neutrophils. , 2014, Annual review of pathology.

[27]  T. Jeitner,et al.  Preparation of 2-nitro-5-thiobenzoate for the routine determination of reagent hypochlorous acid concentrations. , 2013, Analytical biochemistry.

[28]  A. Kettle,et al.  Redox reactions and microbial killing in the neutrophil phagosome. , 2013, Antioxidants & redox signaling.

[29]  D. Owen,et al.  Targeted subendothelial matrix oxidation by myeloperoxidase triggers myosin II-dependent de-adhesion and alters signaling in endothelial cells , 2012, Free radical biology & medicine.

[30]  G. Opdenakker,et al.  VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. , 2012, Blood.

[31]  M. Won,et al.  Synthesis and structure-activity relationship of (E)-phenoxyacrylic amide derivatives as hypoxia-inducible factor (HIF) 1α inhibitors. , 2012, Journal of medicinal chemistry.

[32]  T. Hagen.  Oxygen versus Reactive Oxygen in the Regulation of HIF-1α: The Balance Tips , 2012, Biochemistry research international.

[33]  Li Chen,et al.  20-HETE in neovascularization. , 2012, Prostaglandins & other lipid mediators.

[34]  M. Davies.  Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention , 2010, Journal of clinical biochemistry and nutrition.

[35]  P. Scheffer,et al.  Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? , 2009, Clinical chemistry.

[36]  B. Psaty,et al.  Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. , 2009, The American journal of cardiology.

[37]  A. Kettle,et al.  Hypobromous acid and bromamine production by neutrophils and modulation by superoxide. , 2009, The Biochemical journal.

[38]  T. Couffinhal,et al.  Mouse models to study angiogenesis in the context of cardiovascular diseases. , 2009, Frontiers in bioscience.

[39]  J. Gebicki,et al.  Determination of hydroperoxides in aqueous solutions containing surfactants by the ferrous oxidation-xylenol orange method. , 2009, Acta biochimica Polonica.

[40]  Valérie Ferreira,et al.  VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. , 2008, European journal of cancer.

[41]  Xiaobo Tang,et al.  20-Hydroxyeicosatetraenoic acid inhibits the apoptotic responses in pulmonary artery smooth muscle cells. , 2008, European journal of pharmacology.

[42]  M. Davies,et al.  Mammalian heme peroxidases: from molecular mechanisms to health implications. , 2008, Antioxidants & redox signaling.

[43]  D. Noonan,et al.  Inflammation, inflammatory cells and angiogenesis: decisions and indecisions , 2008, Cancer and Metastasis Reviews.

[44]  Y. Rojanasakul,et al.  Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. , 2007, Cancer research.

[45]  M. Cybulsky,et al.  Getting to the site of inflammation: the leukocyte adhesion cascade updated , 2007, Nature Reviews Immunology.

[46]  A. A. Spector,et al.  Action of epoxyeicosatrienoic acids on cellular function. , 2007, American journal of physiology. Cell physiology.

[47]  Bryan Heit,et al.  Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade , 2006, The Journal of experimental medicine.

[48]  A. Kettle,et al.  Bromination and chlorination reactions of myeloperoxidase at physiological concentrations of bromide and chloride. , 2006, Archives of biochemistry and biophysics.

[49]  S. Ito,et al.  Expression of cytochrome P-450 4 enzymes in the kidney and liver: Regulation by PPAR and species-difference between rat and human , 2006, Molecular and Cellular Biochemistry.

[50]  R. Roman,et al.  Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. , 2005, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[51]  Stanley L Hazen,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[52]  J. Falck,et al.  Inhibitors of cytochrome P450 4A suppress angiogenic responses. , 2005, The American journal of pathology.

[53]  H. Haider,et al.  Therapeutic Angiogenesis for Treatment of Peripheral Vascular Disease , 2004, Growth factors.

[54]  C. Winterbourn,et al.  Extracellular Oxidation by Taurine Chloramine Activates ERK via the Epidermal Growth Factor Receptor* , 2004, Journal of Biological Chemistry.

[55]  Christopher J. Schofield,et al.  Oxygen sensing by HIF hydroxylases , 2004, Nature Reviews Molecular Cell Biology.

[56]  J. Falck,et al.  Smooth Muscle—Specific Expression of CYP4A1 Induces Endothelial Sprouting in Renal Arterial Microvessels , 2004, Circulation research.

[57]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[58]  C. Winterbourn.  Biological reactivity and biomarkers of the neutrophil oxidant, hypochlorous acid. , 2002, Toxicology.

[59]  T. Galeotti,et al.  Reactive Oxygen Species as Downstream Mediators of Angiogenic Signaling by Vascular Endothelial Growth Factor Receptor-2/KDR* , 2002, The Journal of Biological Chemistry.

[60]  C. Winterbourn,et al.  Hypochlorous acid stimulation of the mitogen-activated protein kinase pathway enhances cell survival. , 2001, Archives of biochemistry and biophysics.

[61]  M. Davies,et al.  Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. , 2001, Chemical research in toxicology.

[62]  J. Pullar,et al.  Glutathione Oxidation by Hypochlorous Acid in Endothelial Cells Produces Glutathione Sulfonamide as a Major Product but Not Glutathione Disulfide* , 2001, The Journal of Biological Chemistry.

[63]  A. Kettle,et al.  Thiocyanate and chloride as competing substrates for myeloperoxidase. , 1997, The Biochemical journal.

[64]  S. L. Hazen,et al.  3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. , 1997, The Journal of clinical investigation.

[65]  R. Roman,et al.  Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. , 1994, The American journal of physiology.

[66]  H. Dunford,et al.  Spectral and kinetic studies on the formation of myeloperoxidase compounds I and II: roles of hydrogen peroxide and superoxide. , 1994, Biochemistry.

[67]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[68]  N. Abraham,et al.  Renal cytochrome P-450-arachidonic acid metabolism: localization and hormonal regulation in SHR. , 1992, The American journal of physiology.

[69]  M. Cybulsky,et al.  Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. , 1987, The American journal of pathology.

[70]  J. Schultz,et al.  Studies on the chlorinating activity of myeloperoxidase. , 1976, The Journal of biological chemistry.

[71]  W. Ostrowski,et al.  Chloramines as intermediates of oxidation reaction of amino acids by myeloperoxidase. , 1971, Biochimica et biophysica acta.

[72]  S. Klebanoff.  Myeloperoxidase: Contribution to the Microbicidal Activity of Intact Leukocytes , 1970, Science.

[73]  A. Hussain,et al.  Quantitative spectrophotometric methods for determination of sodium hypochlorite in aqueous solutions. , 1970, Journal of pharmaceutical sciences.

[74]  J. Schultz,et al.  MYELOPEROXIDASE OF THE LEUCOCYTE OF NORMAL HUMAN BLOOD. II. ISOLATION, SPECTROPHOTOMETRY, AND AMINO ACID ANALYSIS. , 1964, Biochemistry.

[75]  J. Schultz,et al.  Myeloperoxidase of the leucocyte of normal human blood. I. Content and localization. , 1962, Archives of biochemistry and biophysics.